[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAqJH7a16lY_lmTw5whXgm6AwyT8EbHdjyZij6tjH46g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"Johns Hopkins Bloomberg School of Public Health",[4],363,false,53,39,1660258,5,292,[14,17,19,22,25,28,30,32],{"name":15,"count":16},"HIV Infections",20,{"name":18,"count":16},"Obesity",{"name":20,"count":21},"HIV",18,{"name":23,"count":24},"Surveys and Questionnaires",11,{"name":26,"count":27},"Noncommunicable Diseases",10,{"name":29,"count":27},"Depression",{"name":31,"count":27},"Anxiety",{"name":33,"count":34},"Substance Use",9,[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04009343","Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials","2020-08-24","Artemether-lumefantrine",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06600711","Nitazoxanide for Treatment of Cryptosporidium in Children","2028-12","Nitazoxanide",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07553286","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial","2028-12-31","A package of oral health interventions, including a daily antiseptic oral rinse",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07433426","The Impact of Shigellosis and Recommended Treatment in Children","2029-08","Azithromycin",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,89,114,138,156,181,234,258,284,302,328,346,370,395,420,445,473,491,516,553,589,611,645,682,704,744,772,790,808,826,844,869,896,914,941,968,997,1015,1039,1057,1082,1107,1125,1149,1174,1192,1218,1244,1278,1304,1322,1349,1367,1391,1409,1435,1460,1484,1502,1520,1545,1563,1591,1609,1627,1653,1671,1689,1707,1731,1756,1774,1798,1821,1845,1871,1889,1913,1938,1961,1988,2006,2024,2050,2072,2094,2120,2138,2162,2186,2211,2240,2266,2292],{"intervention":45,"totalTrials":65,"cells":66},1,{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":74,"PHASE4":85,"NA":87},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[],{"trials":75,"activeCount":65,"soonestReadout":44},[76],{"nctId":42,"briefTitle":43,"status":77,"phases":78,"primaryCompletion":44,"completion":79,"start":80,"enrollment":81,"conditions":82,"interventions":84},"NOT_YET_RECRUITING",[60],"2030-05","2026-06-30",480,[83],"Cryptosporidiosis",[45],{"trials":86,"activeCount":69},[],{"trials":88,"activeCount":69},[],{"intervention":50,"totalTrials":65,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":110,"NA":112},{"trials":92,"activeCount":69},[],{"trials":94,"activeCount":69},[],{"trials":96,"activeCount":69},[],{"trials":98,"activeCount":65,"soonestReadout":49},[99],{"nctId":47,"briefTitle":48,"status":77,"phases":100,"primaryCompletion":49,"completion":49,"start":101,"enrollment":102,"conditions":103,"interventions":109},[60],"2026-07-01",2280,[104,105,106,107,108],"Preterm Birth","Low Birth Weight","Small Vulnerable Newborn","Small-for-gestational Age","Periodontal Disease",[50],{"trials":111,"activeCount":69},[],{"trials":113,"activeCount":69},[],{"intervention":40,"totalTrials":65,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":134,"NA":136},{"trials":117,"activeCount":69},[],{"trials":119,"activeCount":69},[],{"trials":121,"activeCount":69},[],{"trials":123,"activeCount":65,"soonestReadout":39},[124],{"nctId":37,"briefTitle":38,"status":125,"phases":126,"primaryCompletion":39,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"ACTIVE_NOT_RECRUITING",[59,60],"2026-12","2019-06-19",182,[131],"Uncomplicated Falciparum Malaria",[40,133],"Dihydroartemisinin-piperaquine",{"trials":135,"activeCount":69},[],{"trials":137,"activeCount":69},[],{"intervention":133,"totalTrials":65,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":152,"NA":154},{"trials":141,"activeCount":69},[],{"trials":143,"activeCount":69},[],{"trials":145,"activeCount":69},[],{"trials":147,"activeCount":65,"soonestReadout":39},[148],{"nctId":37,"briefTitle":38,"status":125,"phases":149,"primaryCompletion":39,"completion":127,"start":128,"enrollment":129,"conditions":150,"interventions":151},[59,60],[131],[40,133],{"trials":153,"activeCount":69},[],{"trials":155,"activeCount":69},[],{"intervention":55,"totalTrials":65,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":159,"activeCount":69},[],{"trials":161,"activeCount":69},[],{"trials":163,"activeCount":65,"soonestReadout":54},[164],{"nctId":52,"briefTitle":53,"status":165,"phases":166,"primaryCompletion":54,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":174},"RECRUITING",[59],"2030-08","2026-03-18",700,[171,172,173],"Diarrhea Infectious","Shigella","Growth & Development",[55],{"trials":176,"activeCount":69},[],{"trials":178,"activeCount":69},[],{"trials":180,"activeCount":69},[],{"intervention":182,"totalTrials":183,"cells":184},"Chlorhexidine",3,{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":205,"PHASE4":207,"NA":232},{"trials":186,"activeCount":69},[],{"trials":188,"activeCount":69},[],{"trials":190,"activeCount":69},[191],{"nctId":192,"briefTitle":193,"status":194,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":202},"NCT02788786","Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal","COMPLETED",[59],"2016-11-15","2016-06-27",175,[200,201],"Periodontitis","Premature Birth of Newborn",[182,203,204],"Cetylpyridinium chloride","Salt and Water",{"trials":206,"activeCount":69},[],{"trials":208,"activeCount":69},[209,222],{"nctId":210,"briefTitle":211,"status":194,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":221},"NCT04171817","Animal-Assisted Visitation Program Chlorhexidine Trial",[61],"2025-09-01","2026-04-01","2023-05-01",45,[218,219,220],"Methicillin-resistant Staphylococcus Aureus","Clostridium Difficile","Pseudomonas Aeruginosa",[182],{"nctId":223,"briefTitle":224,"status":194,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT00198679","Effect of Chlorhexidine Skin Cleansing on Skin Flora",[61],"2005-03","2004-03",210,[230],"Skin Diseases, Infectious",[182],{"trials":233,"activeCount":69},[],{"intervention":235,"totalTrials":65,"cells":236},"Gentamicin in Uniject Pre-filled syringe",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":256},{"trials":238,"activeCount":69},[],{"trials":240,"activeCount":69},[],{"trials":242,"activeCount":69},[],{"trials":244,"activeCount":69},[],{"trials":246,"activeCount":69},[247],{"nctId":248,"briefTitle":249,"status":194,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"conditions":253,"interventions":255},"NCT00198601","Determination of Gentamicin Dosing in Neonatal Patients",[61],"2005-07","2003-08",[254],"Infection",[235],{"trials":257,"activeCount":69},[],{"intervention":259,"totalTrials":65,"cells":260},"Aquaphor",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":282},{"trials":262,"activeCount":69},[],{"trials":264,"activeCount":69},[],{"trials":266,"activeCount":69},[],{"trials":268,"activeCount":69},[],{"trials":270,"activeCount":69},[271],{"nctId":272,"briefTitle":273,"status":194,"phases":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT00162747","Topical Therapy for Prevention of Infections in Preterm Infants",[61],"2005-06","2001-12",600,[279],"Skin Diseases",[259,281],"Sunflower Seed Oil",{"trials":283,"activeCount":69},[],{"intervention":281,"totalTrials":65,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":300},{"trials":287,"activeCount":69},[],{"trials":289,"activeCount":69},[],{"trials":291,"activeCount":69},[],{"trials":293,"activeCount":69},[],{"trials":295,"activeCount":69},[296],{"nctId":272,"briefTitle":273,"status":194,"phases":297,"completion":275,"start":276,"enrollment":277,"conditions":298,"interventions":299},[61],[279],[259,281],{"trials":301,"activeCount":69},[],{"intervention":303,"totalTrials":65,"cells":304},"Vaxelis",{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":326},{"trials":306,"activeCount":69},[],{"trials":308,"activeCount":69},[],{"trials":310,"activeCount":69},[],{"trials":312,"activeCount":69},[],{"trials":314,"activeCount":69},[315],{"nctId":316,"briefTitle":317,"status":194,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT04978818","Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)",[61],"2023-10-26","2022-01-27",333,[323],"Haemophilus Influenzae Type B Infection",[303,325],"PedvaxHIB",{"trials":327,"activeCount":69},[],{"intervention":325,"totalTrials":65,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":69},[],{"trials":333,"activeCount":69},[],{"trials":335,"activeCount":69},[],{"trials":337,"activeCount":69},[],{"trials":339,"activeCount":69},[340],{"nctId":316,"briefTitle":317,"status":194,"phases":341,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":342,"interventions":343},[61],[323],[303,325],{"trials":345,"activeCount":69},[],{"intervention":347,"totalTrials":65,"cells":348},"Highly active antiretroviral therapy",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":368},{"trials":350,"activeCount":69},[],{"trials":352,"activeCount":69},[],{"trials":354,"activeCount":69},[],{"trials":356,"activeCount":69},[],{"trials":358,"activeCount":69},[359],{"nctId":360,"briefTitle":361,"status":194,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":367},"NCT00106171","Anti-HIV Medications for People Recently Infected With HIV",[61],"2012-05","2005-05",113,[15],[347],{"trials":369,"activeCount":69},[],{"intervention":371,"totalTrials":65,"cells":372},"Gardasil",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":393},{"trials":374,"activeCount":69},[],{"trials":376,"activeCount":69},[],{"trials":378,"activeCount":69},[],{"trials":380,"activeCount":69},[],{"trials":382,"activeCount":69},[383],{"nctId":384,"briefTitle":385,"status":194,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT00925288","Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers",[61],"2011-08","2009-10",200,[391],"Human Papillomavirus Infection",[371],{"trials":394,"activeCount":69},[],{"intervention":396,"totalTrials":65,"cells":397},"Mupirocin + Nozin + chlorhexidine gluconate",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":418},{"trials":399,"activeCount":69},[],{"trials":401,"activeCount":69},[],{"trials":403,"activeCount":69},[],{"trials":405,"activeCount":69},[],{"trials":407,"activeCount":69},[408],{"nctId":409,"briefTitle":410,"status":194,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT06210594","Staph Intervention for Effective Local Defense",[61],"2025-11-14","2024-04-01",78,[416],"Staphylococcus Aureus Infection",[396],{"trials":419,"activeCount":69},[],{"intervention":421,"totalTrials":65,"cells":422},"fluticasone",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":443},{"trials":424,"activeCount":69},[],{"trials":426,"activeCount":69},[],{"trials":428,"activeCount":69},[],{"trials":430,"activeCount":69},[],{"trials":432,"activeCount":69},[433],{"nctId":434,"briefTitle":435,"status":194,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT00705341","MethaCholine Bronchoprovocation Study (MeCIS)",[61],"2010-02","2009-01",219,[441],"Asthma",[421],{"trials":444,"activeCount":69},[],{"intervention":446,"totalTrials":65,"cells":447},"Oral Cholera Vaccine",{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":471},{"trials":449,"activeCount":69},[],{"trials":451,"activeCount":69},[],{"trials":453,"activeCount":69},[],{"trials":455,"activeCount":69},[],{"trials":457,"activeCount":69},[458],{"nctId":459,"briefTitle":460,"status":194,"phases":461,"primaryCompletion":462,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":469},"NCT03373669","Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine",[61],"2019-10-16","2020-12-01","2017-11-16",120,[467,468],"Cholera","Vibrio Cholerae Infection",[446,470],"Adjusted Dose Oral Cholera Vaccine",{"trials":472,"activeCount":69},[],{"intervention":470,"totalTrials":65,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":489},{"trials":476,"activeCount":69},[],{"trials":478,"activeCount":69},[],{"trials":480,"activeCount":69},[],{"trials":482,"activeCount":69},[],{"trials":484,"activeCount":69},[485],{"nctId":459,"briefTitle":460,"status":194,"phases":486,"primaryCompletion":462,"completion":463,"start":464,"enrollment":465,"conditions":487,"interventions":488},[61],[467,468],[446,470],{"trials":490,"activeCount":69},[],{"intervention":492,"totalTrials":65,"cells":493},"Seasonal Inactivated Influenza Vaccine",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":514},{"trials":495,"activeCount":69},[],{"trials":497,"activeCount":69},[],{"trials":499,"activeCount":69},[],{"trials":501,"activeCount":69},[],{"trials":503,"activeCount":69},[504],{"nctId":505,"briefTitle":506,"status":194,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT01978262","Immune and Hormone Response to Influenza Vaccine",[61],"2017-08","2013-10",103,[512],"Healthy",[492],{"trials":515,"activeCount":69},[],{"intervention":517,"totalTrials":518,"cells":519},"Vitamin A",2,{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":537,"PHASE4":549,"NA":551},{"trials":521,"activeCount":69},[],{"trials":523,"activeCount":69},[],{"trials":525,"activeCount":69},[526],{"nctId":527,"briefTitle":528,"status":194,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00198718","Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates",[59],"2001-05","2020-12-31","1997-11",28220,[535,20],"Vitamin A Deficiency",[517],{"trials":538,"activeCount":69},[539],{"nctId":540,"briefTitle":541,"status":194,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT00114868","Vitamin A Supplementation in Newborns Study",[60],"2001-04","1998-06",14035,[547],"Infant, Newborn",[517],{"trials":550,"activeCount":69},[],{"trials":552,"activeCount":69},[],{"intervention":554,"totalTrials":518,"cells":555},"Ganciclovir",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":585,"NA":587},{"trials":557,"activeCount":69},[],{"trials":559,"activeCount":69},[],{"trials":561,"activeCount":69},[],{"trials":563,"activeCount":69},[564,576],{"nctId":565,"briefTitle":566,"status":194,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":574},"NCT00000134","Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)",[60],"1995-03","1992-12",279,[15,572,573],"Acquired Immunodeficiency Syndrome","Cytomegalovirus Retinitis",[554,575],"Foscarnet",{"nctId":577,"briefTitle":578,"status":194,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT00000136","Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)",[60],"1991-10","1990-03",234,[15,573],[575,554],{"trials":586,"activeCount":69},[],{"trials":588,"activeCount":69},[],{"intervention":575,"totalTrials":518,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":607,"NA":609},{"trials":592,"activeCount":69},[],{"trials":594,"activeCount":69},[],{"trials":596,"activeCount":69},[],{"trials":598,"activeCount":69},[599,603],{"nctId":565,"briefTitle":566,"status":194,"phases":600,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":601,"interventions":602},[60],[15,572,573],[554,575],{"nctId":577,"briefTitle":578,"status":194,"phases":604,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":605,"interventions":606},[60],[15,573],[575,554],{"trials":608,"activeCount":69},[],{"trials":610,"activeCount":69},[],{"intervention":612,"totalTrials":518,"cells":613},"Methylphenidate",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":631,"PHASE4":641,"NA":643},{"trials":615,"activeCount":69},[],{"trials":617,"activeCount":69},[],{"trials":619,"activeCount":69},[620],{"nctId":621,"briefTitle":622,"status":194,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":630},"NCT01117181","Apathy in Dementia Methylphenidate Trial (ADMET)",[59],"2012-08","2010-06",60,[628,629],"Apathy","Alzheimer's Disease",[612],{"trials":632,"activeCount":69},[633],{"nctId":634,"briefTitle":635,"status":194,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":389,"conditions":639,"interventions":640},"NCT02346201","Apathy in Dementia Methylphenidate Trial 2",[60],"2020-07-15","2016-01",[628,629],[612],{"trials":642,"activeCount":69},[],{"trials":644,"activeCount":69},[],{"intervention":646,"totalTrials":518,"cells":647},"Sofosbuvir",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":666,"PHASE4":678,"NA":680},{"trials":649,"activeCount":69},[],{"trials":651,"activeCount":69},[],{"trials":653,"activeCount":69},[654],{"nctId":655,"briefTitle":656,"status":194,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT02541409","Directly Observed Therapy for HCV in Chennai, India",[59],"2016-12","2015-09",50,[662],"Hepatitis C, Chronic",[646,664,665],"Pegylated Interferon alfa-2a","Ribavirin",{"trials":667,"activeCount":69},[668],{"nctId":669,"briefTitle":670,"status":194,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":676},"NCT03480932","Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]",[59,60],"2018-11-02","2018-02-02",150,[662],[646,677,664],"Daclatasvir",{"trials":679,"activeCount":69},[],{"trials":681,"activeCount":69},[],{"intervention":664,"totalTrials":518,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":694,"PHASE4":700,"NA":702},{"trials":685,"activeCount":69},[],{"trials":687,"activeCount":69},[],{"trials":689,"activeCount":69},[690],{"nctId":655,"briefTitle":656,"status":194,"phases":691,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":692,"interventions":693},[59],[662],[646,664,665],{"trials":695,"activeCount":69},[696],{"nctId":669,"briefTitle":670,"status":194,"phases":697,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":698,"interventions":699},[59,60],[662],[646,677,664],{"trials":701,"activeCount":69},[],{"trials":703,"activeCount":69},[],{"intervention":705,"totalTrials":518,"cells":706},"Placebos",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":723,"PHASE4":740,"NA":742},{"trials":708,"activeCount":69},[],{"trials":710,"activeCount":69},[],{"trials":712,"activeCount":69},[713],{"nctId":714,"briefTitle":715,"status":194,"phases":716,"primaryCompletion":717,"completion":717,"start":638,"enrollment":718,"conditions":719,"interventions":721},"NCT02656420","Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants",[58,59],"2016-03",170,[720],"Environmental Carcinogenesis",[722,705],"Broccoli Sprout-derived Beverage",{"trials":724,"activeCount":69},[725],{"nctId":726,"briefTitle":727,"status":194,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":738},"NCT03683667","Protein Plus: Improving Infant Growth Through Diet and Enteric Health",[59,60],"2020-03-19","2020-03-24","2018-09-23",5283,[734,735,736,737],"Stunting","Malnutrition; Protein","Enteric Pathogens","Campylobacter Infections",[739,705],"Azithromycin Oral Product",{"trials":741,"activeCount":69},[],{"trials":743,"activeCount":69},[],{"intervention":745,"totalTrials":65,"cells":746},"Nevirapine",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":768,"NA":770},{"trials":748,"activeCount":69},[],{"trials":750,"activeCount":69},[],{"trials":752,"activeCount":69},[],{"trials":754,"activeCount":69},[755],{"nctId":756,"briefTitle":757,"status":194,"phases":758,"primaryCompletion":759,"completion":388,"start":760,"enrollment":761,"conditions":762,"interventions":763},"NCT00115648","Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission",[60],"2007-08","2004-04",3300,[15],[745,764,765,766,767],"AZT","NVP and AZT","NVP","NVP+AZT",{"trials":769,"activeCount":69},[],{"trials":771,"activeCount":69},[],{"intervention":764,"totalTrials":65,"cells":773},{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":786,"NA":788},{"trials":775,"activeCount":69},[],{"trials":777,"activeCount":69},[],{"trials":779,"activeCount":69},[],{"trials":781,"activeCount":69},[782],{"nctId":756,"briefTitle":757,"status":194,"phases":783,"primaryCompletion":759,"completion":388,"start":760,"enrollment":761,"conditions":784,"interventions":785},[60],[15],[745,764,765,766,767],{"trials":787,"activeCount":69},[],{"trials":789,"activeCount":69},[],{"intervention":765,"totalTrials":65,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":804,"NA":806},{"trials":793,"activeCount":69},[],{"trials":795,"activeCount":69},[],{"trials":797,"activeCount":69},[],{"trials":799,"activeCount":69},[800],{"nctId":756,"briefTitle":757,"status":194,"phases":801,"primaryCompletion":759,"completion":388,"start":760,"enrollment":761,"conditions":802,"interventions":803},[60],[15],[745,764,765,766,767],{"trials":805,"activeCount":69},[],{"trials":807,"activeCount":69},[],{"intervention":766,"totalTrials":65,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":822,"NA":824},{"trials":811,"activeCount":69},[],{"trials":813,"activeCount":69},[],{"trials":815,"activeCount":69},[],{"trials":817,"activeCount":69},[818],{"nctId":756,"briefTitle":757,"status":194,"phases":819,"primaryCompletion":759,"completion":388,"start":760,"enrollment":761,"conditions":820,"interventions":821},[60],[15],[745,764,765,766,767],{"trials":823,"activeCount":69},[],{"trials":825,"activeCount":69},[],{"intervention":767,"totalTrials":65,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":840,"NA":842},{"trials":829,"activeCount":69},[],{"trials":831,"activeCount":69},[],{"trials":833,"activeCount":69},[],{"trials":835,"activeCount":69},[836],{"nctId":756,"briefTitle":757,"status":194,"phases":837,"primaryCompletion":759,"completion":388,"start":760,"enrollment":761,"conditions":838,"interventions":839},[60],[15],[745,764,765,766,767],{"trials":841,"activeCount":69},[],{"trials":843,"activeCount":69},[],{"intervention":845,"totalTrials":65,"cells":846},"Cidofovir",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":865,"NA":867},{"trials":848,"activeCount":69},[],{"trials":850,"activeCount":69},[],{"trials":852,"activeCount":69},[],{"trials":854,"activeCount":69},[855],{"nctId":856,"briefTitle":857,"status":194,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":864},"NCT00000142","Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)",[59,60],"1996-02","1994-04",64,[15,863],"CMV Cytomegalovirus Retinitis",[845],{"trials":866,"activeCount":69},[],{"trials":868,"activeCount":69},[],{"intervention":870,"totalTrials":65,"cells":871},"Nedocromil",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":892,"NA":894},{"trials":873,"activeCount":69},[],{"trials":875,"activeCount":69},[],{"trials":877,"activeCount":69},[],{"trials":879,"activeCount":69},[880],{"nctId":881,"briefTitle":882,"status":194,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":890},"NCT00000575","Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS\u002F2), and IV (CAMPCS\u002F3)",[60],"1999-10","2012-03","1991-09",1041,[441,889],"Lung Diseases",[870,891],"Budesonide",{"trials":893,"activeCount":69},[],{"trials":895,"activeCount":69},[],{"intervention":891,"totalTrials":65,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":904,"PHASE4":910,"NA":912},{"trials":899,"activeCount":69},[],{"trials":901,"activeCount":69},[],{"trials":903,"activeCount":69},[],{"trials":905,"activeCount":69},[906],{"nctId":881,"briefTitle":882,"status":194,"phases":907,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":908,"interventions":909},[60],[441,889],[870,891],{"trials":911,"activeCount":69},[],{"trials":913,"activeCount":69},[],{"intervention":915,"totalTrials":65,"cells":916},"Chlorhexidine 4%",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":937,"NA":939},{"trials":918,"activeCount":69},[],{"trials":920,"activeCount":69},[],{"trials":922,"activeCount":69},[],{"trials":924,"activeCount":69},[925],{"nctId":926,"briefTitle":927,"status":194,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":936},"NCT01528852","Chlorhexidine Cordcare for Reduction in Neonatal Mortality and Omphalitis",[60],"2014-09-29","2011-05-19",36911,[933,934,935],"Neonatal Mortality","Cord Care","Omphalitis",[915,915],{"trials":938,"activeCount":69},[],{"trials":940,"activeCount":69},[],{"intervention":942,"totalTrials":65,"cells":943},"Calcium aspirin multiple micronutrients",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":964,"NA":966},{"trials":945,"activeCount":69},[],{"trials":947,"activeCount":69},[],{"trials":949,"activeCount":69},[],{"trials":951,"activeCount":69},[952],{"nctId":953,"briefTitle":954,"status":955,"phases":956,"primaryCompletion":80,"completion":957,"start":413,"enrollment":69,"conditions":958,"interventions":963},"NCT05612984","Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth","WITHDRAWN",[60],"2026-12-31",[959,960,961,105,962],"Preterm Labor","Small for Gestational Age at Delivery","Hypertensive Disorder of Pregnancy","Neonatal Death",[942],{"trials":965,"activeCount":69},[],{"trials":967,"activeCount":69},[],{"intervention":969,"totalTrials":65,"cells":970},"Micronutrient (Zinc and Iron) fortification",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":993,"NA":995},{"trials":972,"activeCount":69},[],{"trials":974,"activeCount":69},[],{"trials":976,"activeCount":69},[],{"trials":978,"activeCount":69},[979],{"nctId":980,"briefTitle":981,"status":194,"phases":982,"completion":760,"start":983,"enrollment":984,"conditions":985,"interventions":991},"NCT00255385","Efficacy of Bifidus DR10 and Oligo Saccharides \u002F Micronutrient Fortification of Milk",[60],"2002-04",1200,[986,987,988,989,990],"Diarrhea","Pneumonia","Febrile Illness","Growth","Child Development",[969,992],"Pre and Probiotic fortification",{"trials":994,"activeCount":69},[],{"trials":996,"activeCount":69},[],{"intervention":992,"totalTrials":65,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":69},[],{"trials":1002,"activeCount":69},[],{"trials":1004,"activeCount":69},[],{"trials":1006,"activeCount":69},[1007],{"nctId":980,"briefTitle":981,"status":194,"phases":1008,"completion":760,"start":983,"enrollment":984,"conditions":1009,"interventions":1010},[60],[986,987,988,989,990],[969,992],{"trials":1012,"activeCount":69},[],{"trials":1014,"activeCount":69},[],{"intervention":1016,"totalTrials":65,"cells":1017},"MSL-109",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1035,"NA":1037},{"trials":1019,"activeCount":69},[],{"trials":1021,"activeCount":69},[],{"trials":1023,"activeCount":69},[],{"trials":1025,"activeCount":69},[1026],{"nctId":1027,"briefTitle":1028,"status":194,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1034},"NCT00000135","Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)",[59,60],"1996-08","1995-09",209,[15,573],[1016],{"trials":1036,"activeCount":69},[],{"trials":1038,"activeCount":69},[],{"intervention":677,"totalTrials":65,"cells":1040},{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1053,"NA":1055},{"trials":1042,"activeCount":69},[],{"trials":1044,"activeCount":69},[],{"trials":1046,"activeCount":69},[],{"trials":1048,"activeCount":69},[1049],{"nctId":669,"briefTitle":670,"status":194,"phases":1050,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":1051,"interventions":1052},[59,60],[662],[646,677,664],{"trials":1054,"activeCount":69},[],{"trials":1056,"activeCount":69},[],{"intervention":1058,"totalTrials":65,"cells":1059},"Metronidazole gel versus placebo gel",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1078,"NA":1080},{"trials":1061,"activeCount":69},[],{"trials":1063,"activeCount":69},[],{"trials":1065,"activeCount":69},[],{"trials":1067,"activeCount":69},[1068],{"nctId":1069,"briefTitle":1070,"status":194,"phases":1071,"completion":226,"start":1072,"conditions":1073,"interventions":1077},"NCT00140764","Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi",[60],"2003-01",[1074,1075,1076],"Bacterial Vaginosis","Trichomonas Vaginitis","Urogenital Diseases",[1058],{"trials":1079,"activeCount":69},[],{"trials":1081,"activeCount":69},[],{"intervention":1083,"totalTrials":65,"cells":1084},"Esomeprazole",{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1103,"NA":1105},{"trials":1086,"activeCount":69},[],{"trials":1088,"activeCount":69},[],{"trials":1090,"activeCount":69},[],{"trials":1092,"activeCount":69},[1093],{"nctId":1094,"briefTitle":1095,"status":194,"phases":1096,"primaryCompletion":1097,"completion":1097,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1102},"NCT00069823","Study of Acid Reflux in Asthma",[60],"2008-05","2003-09",403,[441,889,1101],"Lung Diseases, Obstructive",[1083],{"trials":1104,"activeCount":69},[],{"trials":1106,"activeCount":69},[],{"intervention":739,"totalTrials":65,"cells":1108},{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1121,"NA":1123},{"trials":1110,"activeCount":69},[],{"trials":1112,"activeCount":69},[],{"trials":1114,"activeCount":69},[],{"trials":1116,"activeCount":69},[1117],{"nctId":726,"briefTitle":727,"status":194,"phases":1118,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":1119,"interventions":1120},[59,60],[734,735,736,737],[739,705],{"trials":1122,"activeCount":69},[],{"trials":1124,"activeCount":69},[],{"intervention":1126,"totalTrials":65,"cells":1127},"Cidofovir intravenous",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1145,"NA":1147},{"trials":1129,"activeCount":69},[],{"trials":1131,"activeCount":69},[],{"trials":1133,"activeCount":69},[],{"trials":1135,"activeCount":69},[1136],{"nctId":1137,"briefTitle":1138,"status":194,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1144},"NCT00000143","Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)",[60],"2000-06","1997-05",61,[573,15],[1126],{"trials":1146,"activeCount":69},[],{"trials":1148,"activeCount":69},[],{"intervention":1150,"totalTrials":65,"cells":1151},"Mebendazole",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1170,"NA":1172},{"trials":1153,"activeCount":69},[],{"trials":1155,"activeCount":69},[],{"trials":1157,"activeCount":69},[],{"trials":1159,"activeCount":69},[1160],{"nctId":1161,"briefTitle":1162,"status":194,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":760,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT00116493","Severe Anemia Treatment Trials, Pakistan",[60],"2007-05",1009,[1167],"Anemia",[1150,1169],"Mebendazole + Multivitamin",{"trials":1171,"activeCount":69},[],{"trials":1173,"activeCount":69},[],{"intervention":1169,"totalTrials":65,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":69},[],{"trials":1179,"activeCount":69},[],{"trials":1181,"activeCount":69},[],{"trials":1183,"activeCount":69},[1184],{"nctId":1161,"briefTitle":1162,"status":194,"phases":1185,"primaryCompletion":1164,"completion":1164,"start":760,"enrollment":1165,"conditions":1186,"interventions":1187},[60],[1167],[1150,1169],{"trials":1189,"activeCount":69},[],{"trials":1191,"activeCount":69},[],{"intervention":1193,"totalTrials":65,"cells":1194},"Rifaximin intervention",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1214,"NA":1216},{"trials":1196,"activeCount":69},[],{"trials":1198,"activeCount":69},[],{"trials":1200,"activeCount":69},[],{"trials":1202,"activeCount":69},[1203],{"nctId":1204,"briefTitle":1205,"status":194,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1213},"NCT02280044","Efficacy of Rifaximin in Preventing Campylobacteriosis",[59,60],"2016-08-09","2014-10",30,[1211,986,1212],"Dysentery","Enteric Campylobacteriosis",[1193],{"trials":1215,"activeCount":69},[],{"trials":1217,"activeCount":69},[],{"intervention":1219,"totalTrials":65,"cells":1220},"Nutritional supplements",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1240,"NA":1242},{"trials":1222,"activeCount":69},[],{"trials":1224,"activeCount":69},[],{"trials":1226,"activeCount":69},[],{"trials":1228,"activeCount":69},[1229],{"nctId":1230,"briefTitle":1231,"status":194,"phases":1232,"primaryCompletion":530,"completion":530,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1239},"NCT00115271","Antenatal Micronutrient Supplementation and Birth Weight",[60],"1999-01",5000,[105,1236,1237,1238],"Infant Mortality","Pregnancy","Nutritional Status",[1219],{"trials":1241,"activeCount":69},[],{"trials":1243,"activeCount":69},[],{"intervention":1245,"totalTrials":518,"cells":1246},"oxfendazole",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1259,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1248,"activeCount":69},[],{"trials":1250,"activeCount":69},[1251],{"nctId":1252,"briefTitle":1253,"status":955,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1255,"enrollment":69,"conditions":1256,"interventions":1258},"NCT01584362","Single Ascending Dose Safety Study of Oxfendazole",[58],"2016-08",[1257],"Tenia Solium Infection",[1245,1245,1245,1245,1245,1245],{"trials":1260,"activeCount":69},[1261],{"nctId":1262,"briefTitle":1263,"status":955,"phases":1264,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":69,"conditions":1268,"interventions":1270},"NCT02636803","Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults",[59],"2020-08","2021-02","2019-11",[1269],"Helminthiasis",[1245,1271],"albendazole",{"trials":1273,"activeCount":69},[],{"trials":1275,"activeCount":69},[],{"trials":1277,"activeCount":69},[],{"intervention":1279,"totalTrials":65,"cells":1280},"Anti-CsbD Bovine IgG",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1282,"activeCount":69},[],{"trials":1284,"activeCount":69},[],{"trials":1286,"activeCount":69},[1287],{"nctId":1288,"briefTitle":1289,"status":194,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1296},"NCT00524004","Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD",[59],"2007-10-26","2007-01-30",36,[1295],"Travelers' Diarrhea",[1279,1297],"Anti-CS17 Bovin IgG",{"trials":1299,"activeCount":69},[],{"trials":1301,"activeCount":69},[],{"trials":1303,"activeCount":69},[],{"intervention":1297,"totalTrials":65,"cells":1305},{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1307,"activeCount":69},[],{"trials":1309,"activeCount":69},[],{"trials":1311,"activeCount":69},[1312],{"nctId":1288,"briefTitle":1289,"status":194,"phases":1313,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1314,"interventions":1315},[59],[1295],[1279,1297],{"trials":1317,"activeCount":69},[],{"trials":1319,"activeCount":69},[],{"trials":1321,"activeCount":69},[],{"intervention":1323,"totalTrials":65,"cells":1324},"killed whole cell oral cholera vaccine",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1326,"activeCount":69},[],{"trials":1328,"activeCount":69},[],{"trials":1330,"activeCount":69},[1331],{"nctId":1332,"briefTitle":1333,"status":194,"phases":1334,"primaryCompletion":1335,"completion":1336,"start":1337,"enrollment":1338,"conditions":1339,"interventions":1342},"NCT03719066","Extended Dose Intervals With Oral Cholera Vaccine in Cameroon",[59],"2020-02-27","2021-10-05","2018-10-23",181,[1340,1341],"Adverse Reaction to Cholera Vaccine","Cholera Vaccination Reaction",[1323],{"trials":1344,"activeCount":69},[],{"trials":1346,"activeCount":69},[],{"trials":1348,"activeCount":69},[],{"intervention":665,"totalTrials":65,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1352,"activeCount":69},[],{"trials":1354,"activeCount":69},[],{"trials":1356,"activeCount":69},[1357],{"nctId":655,"briefTitle":656,"status":194,"phases":1358,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":1359,"interventions":1360},[59],[662],[646,664,665],{"trials":1362,"activeCount":69},[],{"trials":1364,"activeCount":69},[],{"trials":1366,"activeCount":69},[],{"intervention":1368,"totalTrials":65,"cells":1369},"zinc supplementation",{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1371,"activeCount":69},[],{"trials":1373,"activeCount":69},[],{"trials":1375,"activeCount":69},[1376],{"nctId":1377,"briefTitle":1378,"status":194,"phases":1379,"completion":1380,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1384},"NCT00138047","Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa",[59],"2004-09","2003-03",100,[15],[1368],{"trials":1386,"activeCount":69},[],{"trials":1388,"activeCount":69},[],{"trials":1390,"activeCount":69},[],{"intervention":722,"totalTrials":65,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":69},[],{"trials":1396,"activeCount":69},[],{"trials":1398,"activeCount":69},[1399],{"nctId":714,"briefTitle":715,"status":194,"phases":1400,"primaryCompletion":717,"completion":717,"start":638,"enrollment":718,"conditions":1401,"interventions":1402},[58,59],[720],[722,705],{"trials":1404,"activeCount":69},[],{"trials":1406,"activeCount":69},[],{"trials":1408,"activeCount":69},[],{"intervention":1410,"totalTrials":65,"cells":1411},"Buspirone",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1413,"activeCount":69},[],{"trials":1415,"activeCount":69},[],{"trials":1417,"activeCount":69},[1418],{"nctId":1419,"briefTitle":1420,"status":194,"phases":1421,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":1425,"conditions":1426,"interventions":1428},"NCT03587142","Buspirone for Early Satiety and Symptoms of Gastroparesis",[59],"2022-04-15","2022-04-30","2019-08-27",96,[1427],"Gastroparesis",[1410],{"trials":1430,"activeCount":69},[],{"trials":1432,"activeCount":69},[],{"trials":1434,"activeCount":69},[],{"intervention":1436,"totalTrials":65,"cells":1437},"pneumococcal polysaccharide and protein conjugate vaccines",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1439,"activeCount":69},[],{"trials":1441,"activeCount":69},[],{"trials":1443,"activeCount":69},[1444],{"nctId":1445,"briefTitle":1446,"status":194,"phases":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1453},"NCT00142389","Mother's Gift Project",[58,59],"2006-12","2004-08",680,[1452],"Pneumococcal Infections",[1436],{"trials":1455,"activeCount":69},[],{"trials":1457,"activeCount":69},[],{"trials":1459,"activeCount":69},[],{"intervention":1461,"totalTrials":65,"cells":1462},"Broccoli Sprout Extract Beverage",{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1464,"activeCount":69},[],{"trials":1466,"activeCount":69},[],{"trials":1468,"activeCount":69},[1469],{"nctId":1470,"briefTitle":1471,"status":194,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT01437501","Broccoli Sprout Intervention in Qidong, P.R. China",[59],"2012-01","2011-10",291,[720],[1461],{"trials":1479,"activeCount":69},[],{"trials":1481,"activeCount":69},[],{"trials":1483,"activeCount":69},[],{"intervention":203,"totalTrials":65,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1496,"PHASE4":1498,"NA":1500},{"trials":1487,"activeCount":69},[],{"trials":1489,"activeCount":69},[],{"trials":1491,"activeCount":69},[1492],{"nctId":192,"briefTitle":193,"status":194,"phases":1493,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":1494,"interventions":1495},[59],[200,201],[182,203,204],{"trials":1497,"activeCount":69},[],{"trials":1499,"activeCount":69},[],{"trials":1501,"activeCount":69},[],{"intervention":204,"totalTrials":65,"cells":1503},{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1505,"activeCount":69},[],{"trials":1507,"activeCount":69},[],{"trials":1509,"activeCount":69},[1510],{"nctId":192,"briefTitle":193,"status":194,"phases":1511,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":1512,"interventions":1513},[59],[200,201],[182,203,204],{"trials":1515,"activeCount":69},[],{"trials":1517,"activeCount":69},[],{"trials":1519,"activeCount":69},[],{"intervention":1521,"totalTrials":65,"cells":1522},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1524,"activeCount":69},[],{"trials":1526,"activeCount":69},[],{"trials":1528,"activeCount":69},[1529],{"nctId":1530,"briefTitle":1531,"status":194,"phases":1532,"primaryCompletion":1533,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT02995005","Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus",[58,59],"2023-01-31","2018-05-24",98,[1537],"Hepatitis B",[1521],{"trials":1540,"activeCount":69},[],{"trials":1542,"activeCount":69},[],{"trials":1544,"activeCount":69},[],{"intervention":1271,"totalTrials":65,"cells":1546},{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1548,"activeCount":69},[],{"trials":1550,"activeCount":69},[],{"trials":1552,"activeCount":69},[1553],{"nctId":1262,"briefTitle":1263,"status":955,"phases":1554,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":69,"conditions":1555,"interventions":1556},[59],[1269],[1245,1271],{"trials":1558,"activeCount":69},[],{"trials":1560,"activeCount":69},[],{"trials":1562,"activeCount":69},[],{"intervention":1564,"totalTrials":65,"cells":1565},"CampETEC HBC product",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1567,"activeCount":69},[],{"trials":1569,"activeCount":69},[1570],{"nctId":1571,"briefTitle":1572,"status":194,"phases":1573,"primaryCompletion":1574,"completion":1575,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1580},"NCT06122870","CampETEC Hyperimmune Bovine Colostrum (HBC)",[58],"2024-06-04","2025-06-04","2023-12-04",27,[1579],"Healthy Volunteer",[1564,1581,1582],"ProMilk 85","C. jejuni CG8421 Challenge strain",{"trials":1584,"activeCount":69},[],{"trials":1586,"activeCount":69},[],{"trials":1588,"activeCount":69},[],{"trials":1590,"activeCount":69},[],{"intervention":1581,"totalTrials":65,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":69},[],{"trials":1596,"activeCount":69},[1597],{"nctId":1571,"briefTitle":1572,"status":194,"phases":1598,"primaryCompletion":1574,"completion":1575,"start":1576,"enrollment":1577,"conditions":1599,"interventions":1600},[58],[1579],[1564,1581,1582],{"trials":1602,"activeCount":69},[],{"trials":1604,"activeCount":69},[],{"trials":1606,"activeCount":69},[],{"trials":1608,"activeCount":69},[],{"intervention":1582,"totalTrials":65,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":69},[],{"trials":1614,"activeCount":69},[1615],{"nctId":1571,"briefTitle":1572,"status":194,"phases":1616,"primaryCompletion":1574,"completion":1575,"start":1576,"enrollment":1577,"conditions":1617,"interventions":1618},[58],[1579],[1564,1581,1582],{"trials":1620,"activeCount":69},[],{"trials":1622,"activeCount":69},[],{"trials":1624,"activeCount":69},[],{"trials":1626,"activeCount":69},[],{"intervention":1628,"totalTrials":65,"cells":1629},"Anti CS6 BSIgG product",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1631,"activeCount":69},[],{"trials":1633,"activeCount":69},[1634],{"nctId":1635,"briefTitle":1636,"status":194,"phases":1637,"primaryCompletion":1638,"completion":508,"start":1639,"enrollment":626,"conditions":1640,"interventions":1641},"NCT03040687","Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge",[58],"2017-04","2017-01",[1579],[1628,1642,1643,1644],"Anti B7A BSIgG product","Bovine Immunoglobin Negative Control","B7A- CS6-expressing ETEC challenge strain",{"trials":1646,"activeCount":69},[],{"trials":1648,"activeCount":69},[],{"trials":1650,"activeCount":69},[],{"trials":1652,"activeCount":69},[],{"intervention":1642,"totalTrials":65,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":69},[],{"trials":1658,"activeCount":69},[1659],{"nctId":1635,"briefTitle":1636,"status":194,"phases":1660,"primaryCompletion":1638,"completion":508,"start":1639,"enrollment":626,"conditions":1661,"interventions":1662},[58],[1579],[1628,1642,1643,1644],{"trials":1664,"activeCount":69},[],{"trials":1666,"activeCount":69},[],{"trials":1668,"activeCount":69},[],{"trials":1670,"activeCount":69},[],{"intervention":1643,"totalTrials":65,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":69},[],{"trials":1676,"activeCount":69},[1677],{"nctId":1635,"briefTitle":1636,"status":194,"phases":1678,"primaryCompletion":1638,"completion":508,"start":1639,"enrollment":626,"conditions":1679,"interventions":1680},[58],[1579],[1628,1642,1643,1644],{"trials":1682,"activeCount":69},[],{"trials":1684,"activeCount":69},[],{"trials":1686,"activeCount":69},[],{"trials":1688,"activeCount":69},[],{"intervention":1644,"totalTrials":65,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1699,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":69},[],{"trials":1694,"activeCount":69},[1695],{"nctId":1635,"briefTitle":1636,"status":194,"phases":1696,"primaryCompletion":1638,"completion":508,"start":1639,"enrollment":626,"conditions":1697,"interventions":1698},[58],[1579],[1628,1642,1643,1644],{"trials":1700,"activeCount":69},[],{"trials":1702,"activeCount":69},[],{"trials":1704,"activeCount":69},[],{"trials":1706,"activeCount":69},[],{"intervention":1708,"totalTrials":65,"cells":1709},"H10407",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1723,"PHASE3":1725,"PHASE4":1727,"NA":1729},{"trials":1711,"activeCount":69},[],{"trials":1713,"activeCount":69},[1714],{"nctId":1715,"briefTitle":1716,"status":194,"phases":1717,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":11,"conditions":1721,"interventions":1722},"NCT00198796","Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains",[58],"2007-02-22","2007-05-30","2005-09",[986],[1708],{"trials":1724,"activeCount":69},[],{"trials":1726,"activeCount":69},[],{"trials":1728,"activeCount":69},[],{"trials":1730,"activeCount":69},[],{"intervention":1732,"totalTrials":65,"cells":1733},"E coli strain H10407 and buffer",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1735,"activeCount":69},[],{"trials":1737,"activeCount":69},[1738],{"nctId":1739,"briefTitle":1740,"status":194,"phases":1741,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1209,"conditions":1745,"interventions":1746},"NCT00844493","Low-dose Challenge Model With Enterotoxigenic E Coli",[58],"2012-02","2013-06","2009-02",[986],[1732,1732,1732,1747],"E coli H10407 and buffer",{"trials":1749,"activeCount":69},[],{"trials":1751,"activeCount":69},[],{"trials":1753,"activeCount":69},[],{"trials":1755,"activeCount":69},[],{"intervention":1747,"totalTrials":65,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":69},[],{"trials":1761,"activeCount":69},[1762],{"nctId":1739,"briefTitle":1740,"status":194,"phases":1763,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1209,"conditions":1764,"interventions":1765},[58],[986],[1732,1732,1732,1747],{"trials":1767,"activeCount":69},[],{"trials":1769,"activeCount":69},[],{"trials":1771,"activeCount":69},[],{"trials":1773,"activeCount":69},[],{"intervention":1775,"totalTrials":65,"cells":1776},"CFA\u002FI and CS17 challenge strain",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1778,"activeCount":69},[],{"trials":1780,"activeCount":69},[1781],{"nctId":1782,"briefTitle":1783,"status":194,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT00564577","Dose-Finding Study of WS6788A and LSN03-016011\u002FA Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17",[58],"2007-06-13","2006-09",13,[1295],[1775],{"trials":1791,"activeCount":69},[],{"trials":1793,"activeCount":69},[],{"trials":1795,"activeCount":69},[],{"trials":1797,"activeCount":69},[],{"intervention":1799,"totalTrials":65,"cells":1800},"anti-CFA\u002FI bovine IgG, and anti-CfaE bovine IgG",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1802,"activeCount":69},[],{"trials":1804,"activeCount":69},[1805],{"nctId":1806,"briefTitle":1807,"status":194,"phases":1808,"completion":1809,"start":1810,"enrollment":1209,"conditions":1811,"interventions":1812},"NCT00435526","Efficacy of Anti-CFA\u002FI and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA\u002FI",[58],"2006-10","2006-03",[986],[1799],{"trials":1814,"activeCount":69},[],{"trials":1816,"activeCount":69},[],{"trials":1818,"activeCount":69},[],{"trials":1820,"activeCount":69},[],{"intervention":1822,"totalTrials":65,"cells":1823},"CS19 expressing ETEC strain",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1837,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1825,"activeCount":69},[],{"trials":1827,"activeCount":69},[1828],{"nctId":1829,"briefTitle":1830,"status":194,"phases":1831,"primaryCompletion":1097,"completion":1832,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1836},"NCT00564863","Dose-Finding Study of CS19 Expressing ETEC Challenge Strains",[58],"2008-09-04","2007-09",25,[1295],[1822],{"trials":1838,"activeCount":69},[],{"trials":1840,"activeCount":69},[],{"trials":1842,"activeCount":69},[],{"trials":1844,"activeCount":69},[],{"intervention":1846,"totalTrials":65,"cells":1847},"Biolean + Diet education",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1849,"activeCount":69},[],{"trials":1851,"activeCount":69},[],{"trials":1853,"activeCount":69},[],{"trials":1855,"activeCount":69},[],{"trials":1857,"activeCount":69},[],{"trials":1859,"activeCount":69},[1860],{"nctId":1861,"briefTitle":1862,"status":1863,"phases":1864,"completion":1865,"start":1866,"enrollment":1867,"conditions":1868,"interventions":1869},"NCT00198809","Use of Herbal Supplements in Weight Loss and Weight Maintenance","TERMINATED",[62],"2004-02","2002-11",250,[18],[1846,1870],"Biolean Free + Diet education",{"intervention":1870,"totalTrials":65,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1874,"activeCount":69},[],{"trials":1876,"activeCount":69},[],{"trials":1878,"activeCount":69},[],{"trials":1880,"activeCount":69},[],{"trials":1882,"activeCount":69},[],{"trials":1884,"activeCount":69},[1885],{"nctId":1861,"briefTitle":1862,"status":1863,"phases":1886,"completion":1865,"start":1866,"enrollment":1867,"conditions":1887,"interventions":1888},[62],[18],[1846,1870],{"intervention":1890,"totalTrials":65,"cells":1891},"Iron-folic acid supplement",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1893,"activeCount":69},[],{"trials":1895,"activeCount":69},[],{"trials":1897,"activeCount":69},[],{"trials":1899,"activeCount":69},[],{"trials":1901,"activeCount":69},[],{"trials":1903,"activeCount":69},[1904],{"nctId":1905,"briefTitle":1906,"status":194,"phases":1907,"primaryCompletion":1908,"completion":1908,"start":1720,"enrollment":1909,"conditions":1910,"interventions":1912},"NCT00198848","Iron Supplementation Among Adolescent Girls in India",[62],"2007-07",2800,[1911],"Iron Deficiency Anemia",[1890],{"intervention":1914,"totalTrials":65,"cells":1915},"Co-Trimoxazole; TMP-SMZ",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1917,"activeCount":69},[],{"trials":1919,"activeCount":69},[],{"trials":1921,"activeCount":69},[],{"trials":1923,"activeCount":69},[],{"trials":1925,"activeCount":69},[],{"trials":1927,"activeCount":69},[1928],{"nctId":1929,"briefTitle":1930,"status":194,"phases":1931,"primaryCompletion":1833,"completion":1833,"start":1932,"enrollment":1933,"conditions":1934,"interventions":1937},"NCT00198627","Etiology, Prevention and Treatment of Neonatal Infections in the Community",[62],"2003-12",16359,[1935,1936],"Bacterial Infection","Infectious Disease",[1914],{"intervention":1939,"totalTrials":65,"cells":1940},"ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1942,"activeCount":69},[],{"trials":1944,"activeCount":69},[],{"trials":1946,"activeCount":69},[],{"trials":1948,"activeCount":69},[],{"trials":1950,"activeCount":69},[],{"trials":1952,"activeCount":69},[1953],{"nctId":1954,"briefTitle":1955,"status":194,"phases":1956,"primaryCompletion":658,"completion":658,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1960},"NCT02773446","Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A",[62],"2016-04",47,[1579],[1939],{"intervention":1962,"totalTrials":65,"cells":1963},"Gentamicin & Amoxicillin x 7days",{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1965,"activeCount":69},[],{"trials":1967,"activeCount":69},[],{"trials":1969,"activeCount":69},[],{"trials":1971,"activeCount":69},[],{"trials":1973,"activeCount":69},[],{"trials":1975,"activeCount":69},[1976],{"nctId":1977,"briefTitle":1978,"status":194,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1985},"NCT00844337","Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh",[62],"2013-09","2009-03",2490,[1984],"Sepsis",[1962,1986,1987],"Penicillin & gentamicin x 2 d + Amoxicillin X 5 d","Standard reference therapy",{"intervention":1986,"totalTrials":65,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1991,"activeCount":69},[],{"trials":1993,"activeCount":69},[],{"trials":1995,"activeCount":69},[],{"trials":1997,"activeCount":69},[],{"trials":1999,"activeCount":69},[],{"trials":2001,"activeCount":69},[2002],{"nctId":1977,"briefTitle":1978,"status":194,"phases":2003,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2004,"interventions":2005},[62],[1984],[1962,1986,1987],{"intervention":1987,"totalTrials":65,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":69},[],{"trials":2011,"activeCount":69},[],{"trials":2013,"activeCount":69},[],{"trials":2015,"activeCount":69},[],{"trials":2017,"activeCount":69},[],{"trials":2019,"activeCount":69},[2020],{"nctId":1977,"briefTitle":1978,"status":194,"phases":2021,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2022,"interventions":2023},[62],[1984],[1962,1986,1987],{"intervention":2025,"totalTrials":65,"cells":2026},"Shanchol",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2028,"activeCount":69},[],{"trials":2030,"activeCount":69},[],{"trials":2032,"activeCount":69},[],{"trials":2034,"activeCount":69},[],{"trials":2036,"activeCount":69},[],{"trials":2038,"activeCount":69},[2039],{"nctId":2040,"briefTitle":2041,"status":1863,"phases":2042,"primaryCompletion":2043,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2049},"NCT02499172","Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi",[62],"2016-10-30","2015-06",2758,[2047,2048,467],"Miscarriage","Stillbirth",[2025],{"intervention":2051,"totalTrials":65,"cells":2052},"Trivalent Inactivated Influenza vaccine",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2054,"activeCount":69},[],{"trials":2056,"activeCount":69},[],{"trials":2058,"activeCount":69},[],{"trials":2060,"activeCount":69},[],{"trials":2062,"activeCount":69},[],{"trials":2064,"activeCount":69},[2065],{"nctId":2066,"briefTitle":2067,"status":194,"phases":2068,"primaryCompletion":1742,"completion":1742,"start":1473,"enrollment":16,"conditions":2069,"interventions":2071},"NCT01522248","Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study",[62],[2070],"Influenza Virus Vaccine",[2051],{"intervention":2073,"totalTrials":65,"cells":2074},"Zinc",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2076,"activeCount":69},[],{"trials":2078,"activeCount":69},[],{"trials":2080,"activeCount":69},[],{"trials":2082,"activeCount":69},[],{"trials":2084,"activeCount":69},[],{"trials":2086,"activeCount":69},[2087],{"nctId":2088,"briefTitle":2089,"status":194,"phases":2090,"primaryCompletion":1449,"completion":1449,"start":1098,"enrollment":2091,"conditions":2092,"interventions":2093},"NCT00198666","Efficacy of Zinc in the Treatment of Pneumonia",[62],299,[987],[2073],{"intervention":2095,"totalTrials":65,"cells":2096},"DepoSubQ Provera 104 in Uniject",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2098,"activeCount":69},[],{"trials":2100,"activeCount":69},[],{"trials":2102,"activeCount":69},[],{"trials":2104,"activeCount":69},[],{"trials":2106,"activeCount":69},[],{"trials":2108,"activeCount":69},[2109],{"nctId":2110,"briefTitle":2111,"status":194,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":2115,"conditions":2116,"interventions":2118},"NCT01578447","Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda",[62],"2013-03","2012-04",356,[2117],"Acceptability of Different Contraceptive Injection Types",[2095,2119],"Intramuscular DMPA",{"intervention":2119,"totalTrials":65,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2123,"activeCount":69},[],{"trials":2125,"activeCount":69},[],{"trials":2127,"activeCount":69},[],{"trials":2129,"activeCount":69},[],{"trials":2131,"activeCount":69},[],{"trials":2133,"activeCount":69},[2134],{"nctId":2110,"briefTitle":2111,"status":194,"phases":2135,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":2115,"conditions":2136,"interventions":2137},[62],[2117],[2095,2119],{"intervention":2139,"totalTrials":65,"cells":2140},"DietPro",{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2149,"NA":2151},{"trials":2142,"activeCount":69},[],{"trials":2144,"activeCount":69},[],{"trials":2146,"activeCount":69},[],{"trials":2148,"activeCount":69},[],{"trials":2150,"activeCount":69},[],{"trials":2152,"activeCount":69},[2153],{"nctId":2154,"briefTitle":2155,"status":194,"phases":2156,"completion":2157,"start":2158,"enrollment":1209,"conditions":2159,"interventions":2161},"NCT00198952","Effects of Herbal Products on Metabolism and Hunger",[62],"2001-03","2000-02",[18,2160],"Metabolism",[2139],{"intervention":2163,"totalTrials":65,"cells":2164},"Chlorhexidine 4.0%",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2166,"activeCount":69},[],{"trials":2168,"activeCount":69},[],{"trials":2170,"activeCount":69},[],{"trials":2172,"activeCount":69},[],{"trials":2174,"activeCount":69},[],{"trials":2176,"activeCount":69},[2177],{"nctId":2178,"briefTitle":2179,"status":194,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2185},"NCT00719329","Impact of Chlorhexidine Cleansing on Bacteria Colonizing the Umbilical Cord of Infants in Bangladesh",[62],"2009-09","2008-08",1931,[254],[2163],{"intervention":2187,"totalTrials":65,"cells":2188},"standard-titer measles vaccine",{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2197,"NA":2199},{"trials":2190,"activeCount":69},[],{"trials":2192,"activeCount":69},[],{"trials":2194,"activeCount":69},[],{"trials":2196,"activeCount":69},[],{"trials":2198,"activeCount":69},[],{"trials":2200,"activeCount":69},[2201],{"nctId":2202,"briefTitle":2203,"status":194,"phases":2204,"completion":1380,"start":2205,"enrollment":169,"conditions":2206,"interventions":2210},"NCT00247091","Impact of HIV on Measles and Measles Immunisation",[],"2000-05",[2207,2208,2209],"HIV Infection","Measles","Children",[2187],{"intervention":2212,"totalTrials":65,"cells":2213},"Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2220,"PHASE4":2222,"NA":2224},{"trials":2215,"activeCount":69},[],{"trials":2217,"activeCount":69},[],{"trials":2219,"activeCount":69},[],{"trials":2221,"activeCount":69},[],{"trials":2223,"activeCount":69},[],{"trials":2225,"activeCount":69},[2226],{"nctId":2227,"briefTitle":2228,"status":194,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2239},"NCT03930017","Pregnancy, Arsenic and Immune Response",[],"2020-01-06","2018-10-14",784,[2234,2235,2236,2237,2238],"Arsenic--Toxicology","Immunologic Disorders Complicating Pregnancy","Vaccine Response Impaired","Micronutrient Deficiency","Influenza",[2212],{"intervention":2241,"totalTrials":65,"cells":2242},"Narcan Nasal Product",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2244,"activeCount":69},[],{"trials":2246,"activeCount":69},[],{"trials":2248,"activeCount":69},[],{"trials":2250,"activeCount":69},[],{"trials":2252,"activeCount":69},[],{"trials":2254,"activeCount":69},[2255],{"nctId":2256,"briefTitle":2257,"status":194,"phases":2258,"primaryCompletion":2259,"completion":2260,"start":2261,"enrollment":2262,"conditions":2263,"interventions":2265},"NCT04212364","An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses",[62],"2023-12-29","2023-12-31","2019-03-15",614,[2264],"Overdose",[2241],{"intervention":2267,"totalTrials":65,"cells":2268},"Duloxetine, Vortioxetine",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2270,"activeCount":69},[],{"trials":2272,"activeCount":69},[],{"trials":2274,"activeCount":69},[],{"trials":2276,"activeCount":69},[],{"trials":2278,"activeCount":69},[],{"trials":2280,"activeCount":69},[2281],{"nctId":2282,"briefTitle":2283,"status":194,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2291},"NCT05267873","Combining Data Sources to Identify Effect Moderation for Personalized Mental Health",[],"2021-12-31","2024-12-01","2015-01-01",9586,[2290],"Depressive Disorder, Major",[2267],{"intervention":2293,"totalTrials":65,"cells":2294},"Amlodipine",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2296,"activeCount":69},[],{"trials":2298,"activeCount":69},[],{"trials":2300,"activeCount":69},[],{"trials":2302,"activeCount":69},[],{"trials":2304,"activeCount":69},[],{"trials":2306,"activeCount":69},[2307],{"nctId":2308,"briefTitle":2309,"status":194,"phases":2310,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2317},"NCT04521582","Management of Hypertension Utilizing Trained Community Health Worker in Rural Municipalities of Nepal",[62],"2022-04-20","2022-07-20","2021-04-27",1428,[2316],"Hypertension,Essential",[2293]]